Finance Watch: Mega-Rounds Balance Out Influx Of Smaller VC Deals
Average Deal Size Is Up But Falling As Investment Dips
Private Company Edition: The amount of venture capital investment in biopharma companies has shrunk from quarter to quarter, but the average deal size remained high until the third quarter. Larger rounds from Treeline, Odyssey and Neumora offset a plethora of smaller VC financings early in Q4.
